FrÃ©dÃ©ric Perros

List of Publications by Year
in descending order

139	10,103	44069 48	34986 98
papers	citations	h-index	g-index

146	146	146	10799
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Single-cell RNA sequencing reveals that <i>BMPR2</i> mutation regulates right ventricular function <i>via ID</i> genes. European Respiratory Journal, 2022, 60, 2100327.	6.7	5
2	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest, 2021, 159, 1197-1207.	0.8	14
3	Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms. Cells, 2021, 10, 477.	4.1	16
4	Central Role of Dendritic Cells in Pulmonary Arterial Hypertension in Human and Mice. International Journal of Molecular Sciences, 2021, 22, 1756.	4.1	12
5	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. Cardiovascular Research, 2021, 117, 2474-2488.	3.8	20
6	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000653.	6.7	16
7	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. Communications Biology, 2021, 4, 1002.	4.4	3
8	Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315.	3.2	8
9	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 210161.	7.1	5
10	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 148-157.	5.6	53
11	In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression. Respiratory Research, 2020, 21, 186.	3.6	20
12	Description, Staging and Quantification of Pulmonary Artery Angiophagy in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension. Biomedicines, 2020, 8, 493.	3.2	2
13	Vitamin D deficiency downregulates TASK-1 channels and induces pulmonary vascular dysfunction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L627-L640.	2.9	19
14	Oral 15-Hydroxyeicosatetraenoic Acid Induces Pulmonary Hypertension in Mice by Triggering T Cellâ€“Dependent Endothelial Cell Apoptosis. Hypertension, 2020, 76, 985-996.	2.7	15
15	Pulmonary capillary haemangiomatosis: a distinct entity?. European Respiratory Review, 2020, 29, 190168.	7.1	17
16	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 843-852.	5.6	12
17	Phenotype and outcome of pulmonary arterial hypertension patients carrying a <i>TBX4</i> mutation. European Respiratory Journal, 2020, 55, 1902340.	6.7	40
18	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary venoâ€occlusive disease. Pulmonary Circulation, 2020, 10, 1-4.	1.7	4

#	Article	IF	Citations
19	Familial pulmonary arterial hypertension by <i>KDR</i> heterozygous loss of function. European Respiratory Journal, 2020, 55, 1902165.	6.7	49
20	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 118-131.	2.9	24
21	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. , 2020, , 63-70.		2
22	Response by Mendes-Ferreira et al to Letter Regarding Article, â€œBmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertensionâ€. Circulation, 2019, 140, e288-e289.	1.6	0
23	BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1187-1188.	5.6	1
24	Characterization of <i>Kcnk3</i> -Mutated Rat, a Novel Model of Pulmonary Hypertension. Circulation Research, 2019, 125, 678-695.	4.5	70
25	Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous. International Journal of Molecular Sciences, 2019, 20, 3575.	4.1	17
26	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. American Journal of Pathology, 2019, 189, 1159-1175.	3.8	19
27	The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats. International Journal of Molecular Sciences, 2019, 20, 1527.	4.1	17
28	<i>Bmpr2</i> Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. Circulation, 2019, 139, 932-948.	1.6	74
29	The integrated stress response system in cardiovascular disease. Drug Discovery Today, 2018, 23, 920-929.	6.4	22
30	Ca2+ handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy. Journal of Molecular and Cellular Cardiology, 2018, 118, 208-224.	1.9	58
31	NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. Circulation, 2018, 137, 2371-2389.	1.6	75
32	Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation. Journal of Hypertension, 2018, 36, 1164-1177.	0.5	48
33	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. Cardiovascular Research, 2018, 114, 880-893.	3.8	52
34	Respiratory effects of trichloroethylene. Respiratory Medicine, 2018, 134, 47-53.	2.9	37
35	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.6	50
36	Pulmonary hypertension associated with neurofibromatosis type 1. European Respiratory Review, 2018, 27, 180053.	7.1	25

#	Article	IF	Citations
37	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. International Journal of Clinical Pharmacy, 2018, 40, 790-794.	2.1	5
38	Identity crisis in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-5.	1.7	5
39	Late Breaking Abstract - Development of an animal model for group 3 Pulmonary Hypertension. , 2018, , .		1
40	Immune repertoire-based signatures in pre-capillary pulmonary hypertension. , 2018, , .		1
41	Local inhibition of angiogenesis combined with repeated blood clot embolization induces chronic thromboembolic pulmonary hypertension in rabbits. , 2018, , .		0
42	NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension. , 2018, , .		0
43	KCNK3 channel inactivation leads to pulmonary vascular alterations in rat. , 2018, , .		0
44	Fine structural modifications of heparan sulfate sulfation patterns in lung are associated with functional effects in Precapillary Pulmonary Hypertension. , 2018, , .		0
45	Gutâ€“Lung Connection in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 402-405.	2.9	34
46	Use of Î²-Blockers in Pulmonary Hypertension. Circulation: Heart Failure, 2017, 10, .	3.9	56
47	Diagnosis and Classification of 17 Diseases from 1404 Subjects <i>via</i> Pattern Analysis of Exhaled Molecules. ACS Nano, 2017, 11, 112-125.	14.6	386
48	Early Development of Right Ventricular Ischemic Lesions in a Novel Large Animal Model of Acute Right Heart Failure in Chronic Thromboembolic Pulmonary Hypertension. Journal of Cardiac Failure, 2017, 23, 876-886.	1.7	14
49	T-type Ca2+ channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 1631-1641.	4.1	21
50	Bromodomain and extraâ€terminal protein mimic <scp>JQ1</scp> decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. Respirology, 2017, 22, 157-164.	2.3	45
51	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 583-595.	5.6	113
52	Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?. Stem Cell Investigation, 2017, 4, 56-56.	3.0	8
53	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. Oncotarget, 2017, 8, 52995-53016.	1.8	42
54	Bacterial translocation in pulmonary hypertension. , 2017, , .		0

#	Article	IF	Citations
55	Administration of mitomycin results in pulmonary hypertension and vascular remodeling in rabbits. , 2017, , .		0
56	Response to Letter Regarding Article, â€œMitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Modelâ€• Circulation, 2016, 133, e592-3.	1.6	4
57	Transcription Factors, Transcriptional Coregulators, and Epigenetic Modulation in the Control of Pulmonary Vascular Cell Phenotype: Therapeutic Implications for Pulmonary Hypertension (2015) Tj ETQq1 1 0.784314 rgBT /Overlock	1.7	4
58	Pulmonary veno-occlusive disease. European Respiratory Journal, 2016, 47, 1518-1534.	6.7	289
59	Endothelial-to-Mesenchymal Transition. Circulation, 2016, 133, 1734-1737.	1.6	79
60	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1273-1285.	5.6	88
61	Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. Proteomics, 2016, 16, 2637-2649.	2.2	25
62	BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. Pflugers Archiv European Journal of Physiology, 2016, 468, 1969-1983.	2.8	20
63	MicroRNA networks in pulmonary arterial hypertension. Current Opinion in Oncology, 2016, 28, 72-82.	2.4	27
64	Î²-blockers in pulmonary arterial hypertension: generation might matter. European Respiratory Journal, 2016, 47, 682-684.	6.7	3
65	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385.	1.6	141
66	Characterization of a new rat model of heritable PAH. , 2016, , .		0
67	LATE-BREAKING ABSTRACT: Vascular endothelial cells in pulmonary arterial hypertension express a unique spectrum of volatile organic compounds. , 2016, , .		0
68	LATE-BREAKING ABSTRACT: KCNK3 dysfunction contributes to the development of pulmonary arterial hypertension â€“ Characterization of Kcnk3 deficient rats. , 2016, , .		0
69	Does Circulating IL-17 Identify a Subset of Patients With Idiopathic Pulmonary Arterial Hypertension?: Response. Chest, 2015, 148, e132-e133.	0.8	0
70	Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells. Respiratory Research, 2015, 16, 114.	3.6	24
71	A Simple Method to Assess<i>In Vivo</i>Proliferation in Lung Vasculature with EdU: The Case of MMC-Induced PVOD in Rat. Analytical Cellular Pathology, 2015, 2015, 1-6.	1.4	6
72	S6â€…The profiles of JMJD3, UTX and H3K27me3 expression in pulmonary vasculature in rat MCT model of PAH and human iPAH: implications for pulmonary arterial hypertension. Thorax, 2015, 70, A7-A8.	5.6	0

#	Article	IF	Citations
73	T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension. Chest, 2015, 147, 1610-1620.	0.8	72
74	Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function inÂPulmonary Hypertension. Journal of the American College of Cardiology, 2015, 65, 668-680.	2.8	119
75	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	3.8	149
76	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. Circulation, 2015, 131, 1006-1018.	1.6	441
77	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. Circulation, 2015, 132, 834-847.	1.6	103
78	Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 457-467.	0.6	34
79	Bone Morphogenetic Protein Receptor Type II and Inflammation Are Bringing Old Concepts into the New Pulmonary Arterial Hypertension World. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 777-779.	5.6	6
80	Potassium channels in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 1167-1177.	6.7	64
81	miR-223 reverses experimental pulmonary arterial hypertension. American Journal of Physiology - Cell Physiology, 2015, 309, C363-C372.	4.6	103
82	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731.	6.7	80
83	Olfactory receptors in pulmonary arterial hypertension: A novel pathway of vascular remodeling?. , 2015, , .		1
84	LSC Abstract â€“ Glutamatergic signaling through pulmonary vascular NMDA receptors in pulmonary hypertension. , 2015, , .		0
85	Mitomycin-induced pulmonary veno-occlusive disease: Experience from the French pulmonary hypertension network. , 2015, , .		0
86	Pulmonary arterial lesions and interstitial remodeling patterns in histology differentiate EIF2AK4 mutation-carriers from non-carriers with pulmonary veno-occlusive disease. , 2015, , .		0
87	Chemotherapy-induced pulmonary hypertension: Role of alkylating agents. , 2015, , .		3
88	CXCL13 in Tertiary Lymphoid Tissues: Sites of Production Are Different from Sites of Functional Localization. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 369-370.	5.6	4
89	KCNK3: new gene target for pulmonary hypertension?. Expert Review of Respiratory Medicine, 2014, 8, 385-387.	2.5	20
90	Evidence for the Involvement of Type I Interferon in Pulmonary Arterial Hypertension. Circulation Research, 2014, 114, 677-688.	4.5	124

#	Article	IF	Citations
91	Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discovery Today, 2014, 19, 1251-1256.	6.4	48
92	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2014, 15, 65.	3.6	38
93	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 1332-1340.	1.6	141
94	Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 2014, 451, 8-14.	2.1	69
95	Systematic Analysis of Blood Cell Transcriptome in End-Stage Chronic Respiratory Diseases. PLoS ONE, 2014, 9, e109291.	2.5	28
96	Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97.	2.7	226
97	A Proof of Concept for the Detection and Classification of Pulmonary Arterial Hypertension through Breath Analysis with a Sensor Array. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 756-759.	5.6	40
98	The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension. Clinical Reviews in Allergy and Immunology, 2013, 44, 31-38.	6.5	85
99	S142â€...The role of H3K27 methylation in vascular endothelial cell proliferation and function: implications for pulmonary arterial hypertension. Thorax, 2013, 68, A73.1-A73.	5.6	0
100	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 189-196.	5.6	54
101	Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension: A Double-Edge Sword?. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 714-724.	2.1	54
102	Nuclear Factor Îº-B Is Activated in the Pulmonary Vessels of Patients with End-Stage Idiopathic Pulmonary Arterial Hypertension. PLoS ONE, 2013, 8, e75415.	2.5	77
103	The Beneficial Effect of Suramin on Monocrotaline-Induced Pulmonary Hypertension in Rats. PLoS ONE, 2013, 8, e77073.	2.5	11
104	Circulating fibrocytes and pulmonary arterial hypertension. European Respiratory Journal, 2012, 39, 210-212.	6.7	8
105	A Critical Role for p130^{Cas} in the Progression of Pulmonary Hypertension in Humans and Rodents. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 666-676.	5.6	85
106	Inflammation in Pulmonary Arterial Hypertension. Chest, 2012, 141, 210-221.	0.8	333
107	Dysregulated Reninâ€"Angiotensinâ€"Aldosterone System Contributes to Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 780-789.	5.6	309
108	Autoimmunity And Pulmonary Arterial Hypertension: The Role Of Leptin. , 2012, , .		1

#	Article	IF	Citations
109	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 895-904.	6.7	110
110	Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 311-321.	5.6	249
111	Tertiary lymphoid organs in infection and autoimmunity. Trends in Immunology, 2012, 33, 297-305.	6.8	311
112	A study of magnesium deficiency in human and experimental pulmonary hypertension. Magnesium Research, 2012, 25, 21-27.	0.5	2
113	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137.	1.6	548
114	Inflammation in Pulmonary Arterial Hypertension. , 2012, , 213-229.		1
115	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. European Respiratory Journal, 2011, 37, 813-822.	6.7	85
116	A Potential Role For Endothelial Cell Derived IL-33 In The Pathogenesis Of Pulmonary Arterial Hypertension. , 2011, , .		0
117	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respiratory Research, 2011, 12, 119.	3.6	67
118	TLR4 signalling in pulmonary stromal cells is critical for inflammation and immunity in the airways. Respiratory Research, 2011, 12, 125.	3.6	71
119	C-Kitâ€"Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 116-123.	5.6	176
120	Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. European Respiratory Journal, 2011, 37, 1392-1399.	6.7	85
121	Endothelial Cell Nf-Kb Activation Is Increased In Human Idiopathic Pulmonary Arterial Hypertension. , 2011, , .		0
122	P29 Endothelial cell NF-kB activation is increased in human idiopathic PAH. Thorax, 2010, 65, A88-A89.	5.6	0
123	Oxidative Stress Contributes To Pulmonary Hypertension In Rats Exposed To Monocrotaline. , 2010, , .		0
124	Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. European Respiratory Journal, 2010, 36, 1209-1211.	6.7	25
125	S154 Is there a role for IL-33 in the pathogenesis of pulmonary arterial hypertension?. Thorax, 2010, 65, A70-A70.	5.6	4
126	S152 Dexamethasone reverses established monocrotaline-induced pulmonary hypertension in rats and increases pulmonary BMPR2 expression. Thorax, 2010, 65, A68-A69.	5.6	0

#	Article	IF	Citations
127	Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats. European Respiratory Journal, 2009, 34, 731-739.	6.7	2
128	House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nature Medicine, 2009, 15, 410-416.	30.7	977
129	Blockade of CCR4 in a humanized model of asthma reveals a critical role for DCâ€derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 995-1002.	5.7	137
130	Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascular Pharmacology, 2008, 49, 113-118.	2.1	118
131	Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 81-88.	5.6	405
132	Understanding the Role of CD4+CD25^{high} (So-Called Regulatory) T Cells in Idiopathic Pulmonary Arterial Hypertension. Respiration, 2008, 75, 253-256.	2.6	10
133	Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. European Respiratory Journal, 2007, 29, 462-468.	6.7	162
134	Role of Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1041-1047.	5.6	196
135	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Human Pathology, 2007, 38, 893-902.	2.0	291
136	Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. European Respiratory Journal, 2007, 29, 937-943.	6.7	143
137	Current Insights on the Pathogenesis of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 355-364.	2.1	36
138	Inflammation in pulmonary arterial hypertension. European Respiratory Journal, 2003, 22, 358-363.	6.7	532
139	An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	8